Working to Transform the Treatment of Hearing Loss
Frequency’s lead product candidate, FX-322, is designed to activate progenitor cells in the ear to regenerate damaged auditory cells and improve hearing function. FX-322 targets a condition known as sensorineural hearing loss, or SNHL, which impacts more than 90 percent of all people with hearing loss.
FX-322 aims to repair the underlying cause of SNHL and improve overall sound clarity and intelligibility, moving beyond today’s standard of care which focuses on sound amplification.
Our Progenitor Cell Activation Approach
Frequency is a leader in the discovery and development of therapeutics that activate progenitor cells for the treatment of degenerative diseases.
Our small molecule approach aims to activate progenitor cells in specific damaged or injured tissues throughout the body in order to create healthy functional tissues and organs.
March 26, 2020
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial ResultsRead More
February 21, 2020